Following a full submission
AWMSG advice |
|
| Status: Terminated | |
In combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. This medicine was considered by AWMSG Scrutiny Panel on 07/08/2025. It was considered suitable for full HTA assessment by LOWMAG. Following discussion with the company it was agreed at this time not to proceed with an HTA due to insufficient comparative information.
|
|
Medicine details |
|
| Medicine name | pegylated liposomal irinotecan (Onivyde®) |
| Formulation | 4.3 mg/ml concentrate for solution for infusion |
| Reference number | 6200 |
| Indication | As above |
| Company | Servier Laboratories Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | Full |
| Status | Terminated |
| Scrutiny Panel meeting date | 07/08/2025 |
| Date of issue | 06/05/2026 |
| NICE guidance | |
| Further information This medicine was considered by AWMSG Scrutiny Panel on 7 August 2025 and was found suitable for a full HTA assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). A Welsh Patient Access Scheme (WPAS) was agreed in principle through the Commercial Arrangement Scheme Wales Group (CASWG). Following discussion with the company it was agreed, at this time not to proceed with an HTA due to insufficient comparative information. If AWTTC or the company become aware of a significant change, this decision may be reviewed.
|
|